In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on NexGel Inc (NXGL – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.75.
Rahman covers the Healthcare sector, focusing on stocks such as PainReform, Vertex Pharmaceuticals, and Viking Therapeutics. According to TipRanks, Rahman has an average return of -9.6% and a 33.57% success rate on recommended stocks.
NexGel Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.05 and a one-year low of $1.09. Currently, NexGel Inc has an average volume of 86.84K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NXGL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NexGel Inc is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics.
Read More on NXGL:
- NXGL Upcoming Earnings Report: What to Expect?
- NEXGEL to Report Second Quarter 2023 Financial Results on August 14th
- NEXGEL Partners with Enigma Health to Distribute its Leading Products in Retail Stores throughout North America
- NexGel partners with Enigma Health to distribute products in retail stores
